LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Avatud

SektorTervishoid

1.43

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.3900000000000001

Max

1.46

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Aktsiakasum	-0.04
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+177.62% upside

Turustatistika
By TradingEconomics
Turukapital	22M 516M
Eelmine avamishind	1.43
Eelmine sulgemishind	1.43

Uudiste sentiment

By Acuity

50%

168 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. nov 2025, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27. nov 2025, 15:32 UTC

Omandamised, ülevõtmised, äriostud

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27. nov 2025, 23:50 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27. nov 2025, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. nov 2025, 16:05 UTC

Market Talk

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27. nov 2025, 16:04 UTC

Market Talk

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27. nov 2025, 15:54 UTC

Omandamised, ülevõtmised, äriostud

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27. nov 2025, 15:44 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27. nov 2025, 15:43 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27. nov 2025, 15:42 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27. nov 2025, 15:41 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27. nov 2025, 15:11 UTC

Market Talk

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27. nov 2025, 14:26 UTC

Market Talk

Hermes' Outperformance Gap Could Narrow -- Market Talk

27. nov 2025, 14:11 UTC

Market Talk

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27. nov 2025, 14:11 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. nov 2025, 13:35 UTC

Market Talk

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27. nov 2025, 13:33 UTC

Market Talk

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27. nov 2025, 13:22 UTC

Market Talk

Global Equities Roundup: Market Talk

27. nov 2025, 13:22 UTC

Market Talk

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27. nov 2025, 13:17 UTC

Market Talk

LVMH Should Be Able to Recover Next Year -- Market Talk

27. nov 2025, 11:13 UTC

Market Talk

European Gas Prices Come Under Pressure -- Market Talk

27. nov 2025, 11:07 UTC

Tulu

Genting: Positive About Prospects Over Longer Term

27. nov 2025, 11:06 UTC

Tulu

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27. nov 2025, 11:04 UTC

Tulu

Genting: International Travel Demand Expected to Remain Resilient

27. nov 2025, 11:04 UTC

Tulu

Genting: Global Growth Expected to Remain Subdued

27. nov 2025, 11:04 UTC

Tulu

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27. nov 2025, 10:59 UTC

Tulu

Genting Bhd 3Q Net Profit Fell 86% on Year

27. nov 2025, 10:58 UTC

Tulu

Genting Bhd 3Q Rev Rose 14% on Year

27. nov 2025, 10:56 UTC

Tulu

Genting Bhd 3Q Net MYR30.3M

27. nov 2025, 10:56 UTC

Tulu

Genting Bhd 3Q EPS MYR0.0079

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

177.62% tõus

12 kuu keskmine prognoos

Keskmine 3.97 USD 177.62%

Kõrge 6 USD

Madal 1.9 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

168 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.